SARAH CHING-LAN HSU MD
Prescription History 1720583339
Internal Medicine - Hematology & Oncology in San Francisco, CA
NPI Status: Active since March 26, 2018
Contact Information
505 PARNASSUS AVE # 1270
SAN FRANCISCO, CA
ZIP 94143
Phone: (415) 885-7276
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SARAH CHING-LAN HSU MD, an active Hematology & Oncology specialist practicing in San Francisco, CA. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 61 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisone, which accounts for 32 claims alone.
Abiraterone Acetate
Generic Formulation: Abiraterone AcetateSpecialty: Internal MedicineProvider Avg Cost Per Claim
$470.57
State Avg Cost Per Claim
$1,946.49
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.
This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.
Prednisone
Generic Formulation: PrednisoneSpecialty: Internal MedicineProvider Avg Cost Per Claim
$9.44
State Avg Cost Per Claim
$8.18
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SARAH CHING-LAN HSU MD provides transparency into local medical care patterns within San Francisco, CA.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
